Core Insights - Novo Nordisk reported a 16% increase in sales in Danish kroner for the first half of 2025, reaching 154.9 billion Danish kroner, with a 25% increase in operating profit to 72.2 billion Danish kroner [1] - Sales in the diabetes and obesity treatment segment grew by 16% to 145.4 billion Danish kroner, driven primarily by a 56% increase in the obesity treatment segment [1] - The company plans to advance the development of subcutaneous and oral amycretin for weight management and has initiated the REDEFINE 11 trial for CagriSema [1] Regional Performance - Sales in China increased by 6% year-on-year at constant exchange rates, primarily driven by obesity treatment products [2] - Sales in the rare disease segment in China surged by 93%, mainly due to growth in rare blood disorders [2] Future Outlook - For the full year 2025, the company expects sales growth of 8-14% and operating profit growth of 10-16% at constant exchange rates [2] - The sales forecast for 2025 has been adjusted downward due to lower growth expectations in the second half of the year, reflecting slower market expansion and increased competition [2] - The company continues to push for the global launch of Wegovy® and aims to enhance market penetration for both Wegovy® and Ozempic® [2]